Welcome to our dedicated page for Neurometrix SEC filings (Ticker: NURO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
neurometrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. the company maintains an active research effort and has several pipeline programs. the company is located in waltham, massachusetts and was founded as a spinoff from the harvard-mit division of health sciences and technology in 1996. for more information, please visit neurometrix.com. neurometrix markets the following products: quell® wearable pain relief technology™ quell is 100% drug free wearable technology that has changed the lives of people suffering with chronic pain. it combines clinical strength neurostimulation to treat pain with an easy-to-use app that helps people manage pain and reclaim their lives. quell is doctor recommended and designed for people with chronic back pain, arthritic pain, nerve pain, leg and foot pain, among other chronic pain conditions. quell launcNeuroMetrix, Inc. Schedule 13G/A (Amendment No. 2) discloses that The Radoff Family Foundation and Bradley L. Radoff no longer beneficially own any common stock of the company. As of the close of business on June 30, 2025, both Reporting Persons report 0 shares and 0% ownership of the class, indicating they hold no voting or dispositive power over NeuroMetrix shares.
The filing identifies the reporting entities, their principal address and citizenship, confirms the disclosure covers common stock with $0.0001 par value, and includes a certification that the securities were not acquired to influence control of the issuer.
FAQ
What is the current stock price of Neurometrix (NURO)?
What is the market cap of Neurometrix (NURO)?
